3:I[231,["231","static/chunks/231-0fefb1d35a503081.js","669","static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js"],""]
4:I[9275,[],""]
6:I[1343,[],""]
7:I[8173,["231","static/chunks/231-0fefb1d35a503081.js","410","static/chunks/410-427e639415368772.js","185","static/chunks/app/layout-cc68188960cc2107.js"],"Image"]
2:T51b,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does MSB do?","acceptedAnswer":{"@type":"Answer","text":"Mesoblast develops allogeneic mesenchymal stromal cell (MSC) therapies for serious inflammatory conditions. Their lead product, remestemcel-L (Ryoncil), targets acute graft versus host disease, while other candidates are for chronic heart failure and chronic lower back pain."}},{"@type":"Question","name":"Is MSB a good investment?","acceptedAnswer":{"@type":"Answer","text":"As a clinical-stage biotechnology company, MSB offers substantial upside potential if its therapies gain regulatory approval and achieve commercial success. However, it carries significant risks inherent to drug development, including clinical trial failures and regulatory hurdles, making it a speculative investment with high volatility."}},{"@type":"Question","name":"What drives MSB's share price?","acceptedAnswer":{"@type":"Answer","text":"MSB's share price is primarily driven by announcements regarding clinical trial results, regulatory decisions (especially from the FDA), progress in commercialisation partnerships, and successful capital raisings. News regarding competitor therapies or changes in the broader biotech sector can also influence its valuation."}}]}5:["ticker","MSB","d"]
0:["expxC_2cvqaJFzWCHYH4M",[[["",{"children":["asx",{"children":[["ticker","MSB","d"],{"children":["__PAGE__?{\"ticker\":\"MSB\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","MSB","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Mesoblast Limited"," (","MSB",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Mesoblast Limited (ASX: MSB) is an Australian-based biotechnology company focused on developing allogeneic mesenchymal stromal cell (MSC) therapies for inflammatory diseases. Their lead product candidate, remestemcel-L (Ryoncil), is in development for acute graft versus host disease (aGVHD) and has been submitted for FDA approval. The company also has other pipeline candidates, including rexlemestrocel-L, targeting chronic heart failure and chronic lower back pain, operating globally from its Australian base."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$3.2B"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"Price Chart (TradingView)"}],["$","div",null,{"className":"mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400","children":["Embed TradingView widget here for ","MSB",". The production version should load live pricing and technical indicators."]}]]}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Mesoblast is a clinical-stage biotechnology company with a significant market capitalization of A$3.2 billion, reflecting its advanced pipeline and potential market opportunities. Its current position is heavily reliant on the successful navigation of regulatory pathways, particularly for remestemcel-L (Ryoncil) in the US market, which has faced previous delays. As a biotech, the company's financials are characterised by substantial research and development expenses and often net losses, with revenue primarily derived from partnerships or early product sales post-approval.",{"children":"Mesoblast is a clinical-stage biotechnology company with a significant market capitalization of A$3.2 billion, reflecting its advanced pipeline and potential market opportunities. Its current position is heavily reliant on the successful navigation of regulatory pathways, particularly for remestemcel-L (Ryoncil) in the US market, which has faced previous delays. As a biotech, the company's financials are characterised by substantial research and development expenses and often net losses, with revenue primarily derived from partnerships or early product sales post-approval."}],["$","p","The growth outlook for Mesoblast is intrinsically linked to key catalysts such as FDA approval for Ryoncil, positive Phase 3 clinical trial results for its other pipeline candidates, and subsequent commercialisation efforts or strategic partnerships. The company's strategic direction involves securing regulatory approvals, particularly in major markets, and leveraging its proprietary cell therapy platform to address significant unmet medical needs in conditions like aGVHD, heart failure, and chronic back pain. Given its speculative nature, success in these areas would be transformative.",{"children":"The growth outlook for Mesoblast is intrinsically linked to key catalysts such as FDA approval for Ryoncil, positive Phase 3 clinical trial results for its other pipeline candidates, and subsequent commercialisation efforts or strategic partnerships. The company's strategic direction involves securing regulatory approvals, particularly in major markets, and leveraging its proprietary cell therapy platform to address significant unmet medical needs in conditions like aGVHD, heart failure, and chronic back pain. Given its speculative nature, success in these areas would be transformative."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","FDA grants full approval for remestemcel-L (Ryoncil) for acute graft versus host disease, leading to significant market penetration and revenue generation.",{"children":["• ","FDA grants full approval for remestemcel-L (Ryoncil) for acute graft versus host disease, leading to significant market penetration and revenue generation."]}],["$","li","Positive Phase 3 clinical trial results for rexlemestrocel-L in chronic heart failure or chronic lower back pain open pathways for further regulatory submissions and market expansion.",{"children":["• ","Positive Phase 3 clinical trial results for rexlemestrocel-L in chronic heart failure or chronic lower back pain open pathways for further regulatory submissions and market expansion."]}],["$","li","Mesoblast secures a significant global commercialisation partnership for one or more of its advanced therapies, providing substantial upfront payments and ongoing royalties.",{"children":["• ","Mesoblast secures a significant global commercialisation partnership for one or more of its advanced therapies, providing substantial upfront payments and ongoing royalties."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Further regulatory setbacks or outright rejection from the FDA for remestemcel-L (Ryoncil) significantly diminishes its commercial prospects.",{"children":["• ","Further regulatory setbacks or outright rejection from the FDA for remestemcel-L (Ryoncil) significantly diminishes its commercial prospects."]}],["$","li","Ongoing Phase 3 clinical trials for other pipeline candidates yield negative or inconclusive results, leading to further delays or discontinuation of development.",{"children":["• ","Ongoing Phase 3 clinical trials for other pipeline candidates yield negative or inconclusive results, leading to further delays or discontinuation of development."]}],["$","li","The company faces challenges in securing adequate capital for its extensive R&D programs, or competition from rival therapies impacts its market potential.",{"children":["• ","The company faces challenges in securing adequate capital for its extensive R&D programs, or competition from rival therapies impacts its market potential."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Quarterly Activities Report"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Highlights production updates, capital allocation priorities, and FY guidance commentary."}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Investor Presentation"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Strategic outlook with market positioning and growth pipeline."}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does MSB do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does MSB do?"}],["$","p",null,{"className":"text-slate-400","children":"Mesoblast develops allogeneic mesenchymal stromal cell (MSC) therapies for serious inflammatory conditions. Their lead product, remestemcel-L (Ryoncil), targets acute graft versus host disease, while other candidates are for chronic heart failure and chronic lower back pain."}]]}],["$","div","Is MSB a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is MSB a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"As a clinical-stage biotechnology company, MSB offers substantial upside potential if its therapies gain regulatory approval and achieve commercial success. However, it carries significant risks inherent to drug development, including clinical trial failures and regulatory hurdles, making it a speculative investment with high volatility."}]]}],["$","div","What drives MSB's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives MSB's share price?"}],["$","p",null,{"className":"text-slate-400","children":"MSB's share price is primarily driven by announcements regarding clinical trial results, regulatory decisions (especially from the FDA), progress in commercialisation partnerships, and successful capital raisings. News regarding competitor therapies or changes in the broader biotech sector can also influence its valuation."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","5.77"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["14.5","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$3.2B"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"16/12/2004"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L3",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","285.40"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["9.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$140B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","1.66"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["14.7","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$2.4B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.09"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["37.0","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$5","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L3",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L7",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L3","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L3","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L3","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L3","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L3","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L3","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 sm:flex","children":[["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden","children":[["$","span",null,{"children":"AI market insights for ASX investors"}],["$","$L3",null,{"href":"/screener","className":"text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L3",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/7c1fda61599f9f98.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$L8"]]]]]
8:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"MSB share price, analysis & company profile - Mesoblast Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/MSB/"}],["$","meta","5",{"property":"og:title","content":"MSB share price, analysis & company profile - Mesoblast Limited"}],["$","meta","6",{"property":"og:description","content":"Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/MSB/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"MSB share price, analysis & company profile - Mesoblast Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
